New Jersey Headlines

DelveInsight’s, “Alopecia Areata Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Alopecia Areata Pipeline Report

• DelveInsight’s Alopecia Areata pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Alopecia Areata treatment.
• The leading companies working in the Alopecia Areata Market include Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited, and others.
• Promising Alopecia Areata Pipeline Therapies in the various stages of development include Etrasimod, Baricitinib, 5% Minoxidil Topical Foam, Dutasteride, ENERGI-F701, Regaine, and others.
• September 2023: Q32 Bio Inc. announced a study of phase 2 clinical trials for ADX-914. This is a Phase IIa, Randomized, Double-blind, Placebo-controlled, multi-center Proof-of-Concept (POC) study in adult subjects with severe Alopecia Areata (AA). ADX-914 or matching placebo is administered subcutaneously in the clinic setting every 2 weeks for 24 weeks, with follow-up for 12 weeks. Subjects will be randomized 3:1 to drug vs placebo.
• September 2023: Pfizer announced a study of phase 3 clinical trials for PF-06651600. This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.

Request a sample and discover the recent advances in Alopecia Areata Treatment Drugs @ Alopecia Areata Pipeline Report

In the Alopecia Areata pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alopecia Areata collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Alopecia Areata Overview

Alopecia areata (AA) is a form of alopecia that impacts hair follicles, nails, and rarely, the retinal pigment epithelium. It typically presents with round patches and is a type of non-scarring hair loss. A significant feature of the hair follicle is its relative immune privilege, this mainly established by suppression of surface molecules required for presenting auto antigens to CD8+ T lymphocytes (i.e., MHC class I) and by the generation of an inhibitory local signaling environment.

Find out more about Alopecia Areata Therapeutics Assessment @ Alopecia Areata Preclinical and Discovery Stage Products

Alopecia Areata Emerging Drugs Profile

• Deuruxolitinib: Concert Pharmaceuticals
• EQ101: Equillium
• MAX 40070: Maxinovel Pharmaceuticals

Alopecia Areata Pipeline Therapeutics Assessment

There are approx. 18+ key companies which are developing the Alopecia Areata therapies. The Alopecia Areata companies which have their Alopecia Areata drug candidates in the most advanced stage, i.e. phase III include, Concert Pharmaceuticals.

Learn more about the emerging Alopecia Areata Pipeline Therapies @ Alopecia Areata Clinical Trials Assessment

Scope of the Alopecia Areata Pipeline Report

• Coverage- Global
• Alopecia Areata Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Alopecia Areata Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Alopecia Areata Companies- Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited, and others.
• Alopecia Areata Pipeline Therapies- Etrasimod, Baricitinib, 5% Minoxidil Topical Foam, Dutasteride, ENERGI-F701, Regaine, and others.

Dive deep into rich insights for new drugs for Alopecia Areata treatment, Visit @ Alopecia Areata Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Alopecia Areata Executive Summary
3. Alopecia Areata: Overview
4. Alopecia Areata Pipeline Therapeutics
5. Alopecia Areata Therapeutic Assessment
6. Alopecia Areata– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Deuruxolitinib: Concert Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EQ101: Equillium
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MAX 40070: Maxinovel Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Alopecia Areata Key Companies
21. Alopecia Areata Key Products
22. Alopecia Areata- Unmet Needs
23. Alopecia Areata- Market Drivers and Barriers
24. Alopecia Areata- Future Perspectives and Conclusion
25. Alopecia Areata Analyst Views
26. Alopecia Areata Key Companies
27. Appendix

For further information on the Alopecia Areata pipeline therapeutics, reach out to Alopecia Areata Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking